in this paradigm, doctors would in effect be treating population risk rather than individual risk factor thresholds as is current mainstream practice. so, if everyone were given a relevant kind of polypill, the average blood pressure and cholesterol levels in the population would fall, thus reducing overall population risk. perhaps ironically, this is in a sense going in the "opposite" direction from personalized medicine, since mass-produced or fixed-dose-combination polypills are in some tension with the goals of personalized medicine, due to the "fixed" nature of the "dose combinations." proponents of this population-focused approach contend that the advantages of drug consolidation can outweigh any reduction in personalization of drug and/or dose selection. also, depending on the demographic distribution and market size, there may be room for some different alternative versions of certain general fdcs to be manufactured with differences in their respective dosages and/or drugs. a widely distributed polypill could contain three blood pressure medications at low dose: a diuretic, such as hydrochlorothiazide, a beta-blocker such as atenolol, and an ace inhibitor such as lisinopril; and these could be combined with a statin such as simvastatin, aspirin at a dose of 75 mg, and folic acid, which has been shown to reduce the level of homocysteine in the blood, which is another risk factor for heart disease.